Shares of Centrus Energy jumped +10.2% to $108.46 on October 27 after Texas Capital Securities initiated coverage with a Buy rating and a $151 price target — the firm cited Centrus's domestic nuclear enrichment build-out and the global nuclear power renaissance . The call arrives after a punishing stretch: LEU has fallen roughly 72% over the past year and recently grazed its 52-week low of $96.80 . For shareholders, the question is whether today's bounce is the floor or a dead-cat reflex.

  • One Company, No U.S. Competition — For Now. Texas Capital noted Centrus's position as the only commercial-ready U.S.-origin enrichment provider, creating a strong competitive advantage in an industry with high barriers to entry . Its American Centrifuge Plant is the only U.S. facility licensed to enrich HALEU — the specialized fuel needed by next-generation reactors — and one of only two licensed for standard uranium enrichment . That monopoly-like position is powerful, but investors should note TD Cowen simultaneously initiated coverage with a Hold rating, citing elevated capital costs and competitive pressures as concerns .

  • A $3 Billion Backlog Hints at Future Revenue, but It's Conditional. The company's $3 billion backlog of contingent sales commitments for enriched uranium provides visibility into future demand, while its legacy fuel-trading business continues to deliver cash flow . Still, "contingent" matters: Centrus guided 2026 revenue of just $425–$475 million with capital deployment of $350–$500 million , meaning much of its spending right now is going into building factories, not generating profit.

  • The $116 Million Supplier Deal Deepens the Bet. On October 19, Centrus acquired Westerman Holdings for roughly $116 million — about $95 million in cash and $21 million in equity — bringing a critical centrifuge-component maker in-house . The deal added four manufacturing facilities and about 400 employees . Management says it will be accretive to adjusted earnings per share within the first year , but it also drains cash reserves loaded up by a $500 million stock-and-warrant offering priced at $199.64 per share in September — nearly double today's price.

  • Analyst Consensus Is Split, and Dilution Looms. Needham recently cut its price target from $262 to $206, projecting a gross loss of $12.9 million for Q3 2026 . Meanwhile, short interest sits at 5.9 million shares — about 30.4% of the float , a level high enough to fuel sharp squeezes. Those September warrants carry strike prices up to $363 — enormous potential dilution if the stock recovers. Earnings are due November 5; that report will reveal whether Centrus's ambitious spending is translating into progress or burning cash faster than bulls expect.